Use of hormone therapies in disseminated carcinomatosis of the bone marrow associated with hormone receptor-positive breast cancer

Abstract

Disseminated carcinomatosis of the bone marrow (DCBM) is diffusely invasive bone metastasis resulting from solid tumors. DCBM is often associated with disseminated intravascular coagulation (DIC) or hemolytic anemia. Generally, DCBM treatment includes cytotoxic chemotherapy for underlying solid tumors and management of hematological conditions if present. We report a case of DCBM accompanied with DIC in hormone receptor-positive breast cancer. Due to her life-threatening condition, we used hormone therapies, not cytotoxic chemotherapies, to treat her DCBM. With zoledronic acid, her DIC and general condition gradually improved and eventually she could return to her daily life. If DCBM occurs in hormone receptor-positive breast cancer, hormone therapy can be one of the treatment choices.

Chinese abstract

癌症骨髓浸润（DCBM）是由实体瘤引起的弥漫性侵袭性骨转移。DCBM通常伴有弥散性血管内凝血（DIC）或溶血性贫血。一般而言, DCBM治疗包括对潜在的实体瘤进行细胞毒性化疗, 以及对血液状态的管理。我们报道了一例DCBM伴有DIC的激素受体阳性乳腺癌病例。考虑到她的危险状况, 我们使用激素疗法而不是细胞毒性化疗DCBM。应用唑来膦酸后, 她的DIC和全身情况逐渐好转, 最终她可以正常进行日常生活。如果DCBM发生在激素受体阳性乳腺癌患者中, 那么使用激素疗法是一个选择。

Keywords:

• Breast cancer
• disseminated carcinomatosis of the bone marrow
• hormone therapy
• zoledronic acid

View correction statement:

Correction to: Ota et al., Use of hormone therapies in disseminated carcinomatosis of the bone marrow associated with hormone receptor-positive breast cancer

Consent

Written informed consent was obtained from the patient for the publication of the case report and accompanying images. A copy of the consent form has been made available for review by the Editor-in-Chief of this journal.

Disclosure statement

No potential conflict of interest was reported by the authors.